Antivitamin K drugs in stroke prevention. by DI RAIMONDO, D. et al.
Send Orders of Reprints at bspsaif@emirates.net.ae 
 Current Vascular Pharmacology, 2013, 11, 000-000 1 
 1570-1611/13 $58.00+.00 © 2013 Bentham Science Publishers 
Antivitamin K Drugs in Stroke Prevention 
Domenico Di Raimondo*, Antonio Tuttolomondo, Giuseppe Licata° and Antonio Pinto 
U.O.C. di Medicina Vascolare – °U.O.C. di Medicina Interna e Cardioangiologia, Dipartimento Biomedico di Medicina 
Interna e Specialistica, Università degli Studi di Palermo, Palermo, Italy 
Abstract: Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes 
of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. 
Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke de-
pends on whether the underlying cause is cardioembolic or of presumed arterial origin. 
Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial ori-
gin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K an-
tagonists (VKAs) are highly effective in preventing recurrent ischaemic stroke but have important limitations and are thus 
underused. 
Current guidelines still regard Vitamin K Antagonists at INR 2·0–3·0 to be the standard treatment after cerebral ischaemia 
of cardiac origin for patients who can tolerate them. In this setting antiplatelet therapy provides an alternative when oral 
anticoagulation is contraindicated or when patient choice or compliance limits choice of therapy, but is much less effec-
tive than VKAs. Recent trial data performed with new anticogulants such as the factor Xa and thrombin inhibitors will 
need to be taken into account, in order to prevent several of the clinical problems actually related to VKAs use. 
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INTRODUCTION  
 Among the different subtypes of ischaemic strokes, al-
most 20 % are of cardiac origin. Different are the causes of 
cardioembolic stroke, but the most common is the atrial fib-
rillation (AF), a supraventricular arrhythmia. AF is associ-
ated with a four- to fivefold increase in the risk of ischemic 
stroke, and 15% of all ischemic strokes are caused by AF. 
Importantly, this proportion increases substantially with age 
[1].  
 Strategies to reduce risk of recurrence of the cerebral 
ischemia after a transient ischaemic attack (TIA) or ischae-
mic stroke depend, among other interventions, on appropri-
ate use of antiplatelet drugs and anticoagulants after the iden-
tification of the underlying cause of the first event: that is, in 
the greatest part of ischemic strokes, cardioembolic or due to 
atherosclerotis of the arteries [2].  
 The standard therapy to prevent stroke and systemic 
thromboembolism associated with cardiac origin has been 
anticoagulation with a coumarin derivative (or vitamin K 
antagonist [VKA]). However, coumarins have a narrow 
therapeutic index and require ongoing frequent monitoring. 
Newer antithrombotic agents are destined to provide stroke 
prevention therapy without the problems inherent in frequent 
monitoring of the International Normalized Ratio (INR).  
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 Aim of this review is to provide a brief evaluation, in the 
age of new oral anticoagulants, of available data about effec-
tiveness of vitamin K antagonists therapy for the prevention 
of stroke and to discuss the expected benefit of use of anti-
platelet drugs in these patients when VKAs are contraindi-
cated or the compliance of the patients does not allow the use 
of these compounds. 
MAIN CHARACTERISTICS OF VITAMIN K AN-
TAGONISTS (VKAS) 
 The available anticoagulant drugs inhibit various compo-
nents of the clotting cascade. Coumarins cause  carboxyla-
tion and inhibition of vitamin K– dependent clotting factors 
(factors II, VII, IX, and X) and vitamin K–dependent antico-
agulant factors (protein C and S) [3]. Thus, the biological 
effect of coumarins is directly related to the normal half-life 
of these factors and, generally, the full anticoagulant effect is 
not seen for 4 to 7 days after commencing daily therapy [4]. 
As a consequence of this gap, usually bridging therapy with 
another anticoagulant drug, usually low molecular weight 
heparins (LMWHs), is associated to guarantee a potential 
anticoagulant effect until therapeutic INR target is reached 
and the level of VKAs activity becomes therapeutic. 
 Nowadays, VKAs are the standard-of-care oral antico-
agulants for long-term stroke prevention in established car-
dioembolic stroke.  
 The risk of major bleeding is significantly higher with 
coumarins compared with aspirin (2.2 vs 1.3 events per 100 
patient-years) and risk increases with the INR value [5]. An-
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tiplatelet use, advanced age, supratherapeutic INR, and prior 
stroke increase the risk of intracranial hemorrhage (ICH) [6]. 
Advancing age has been presumed to be a risk factor for 
bleeding during anticoagulation perhaps because of the ac-
cumulation of other risk factors such as stroke and more 
widespread use of antiplatelet agents. 
 When needed, rapid reversal of INR might be obtained 
through use of vitamin K infusion, fresh frozen plasma 
(FFP), and/or Factor VIIa. These interventions rapidly re-
verse INR but they have not yet been shown to completely 
reverse all aspects of VKA-associated hemorrhage [7]. 
 A usual clinical problem observed by clinicians who cur-
rently use VKAs is the interactions of these compounds with 
several other drugs [8] and the different therapeutic effect 
observed according to various degree of diet-derived vitamin 
K.  
 Another common clinical problem concerns the optimal 
behavior for patients who are chronically anticoagulated for 
AF, but require a minor or major surgical procedure. Practice 
is highly variable in this circumstance. Some physicians will 
bridge patients with LMWH until the day of the procedure, 
and restart thereafter. Others will simply stop VKAs a week 
before and restart thereafter. A result of imperfect VKAs 
stopping and restarting is the rather common story of presen-
tation for cardioembolic stroke of a patient who stopped their 
VKA and had a colonoscopy yesterday or is due for a small 
biopsy but never gets there because they are admitted with a 
stroke. 
 There are reasonable data to suggest that minor proce-
dures such as tooth extractions, skin biopsies, pacemaker 
placement, and cataract removal do not require cessation of 
VKAs [8]. This information is not widely known and many 
surgeons refuse to perform such procedures while patients 
are on VKAs. Education is required. Practically, invasive 
procedures will require the cessation of VKAs but it remains 
unknown if bridging with LMWH is appropriate. It seems 
likely that a risk stratification process could be developed for 
this situation. Further data are needed to better standardize 
behavior of clinicians in these situations to provide maxi-
mum protection to anticoagulated patients. 
ANTIPLATELET VS ANTICOAGULANTS IN SEC-
ONDARY PREVENTION AFTER CEREBRAL 
ISCHAEMIA OF ARTERIAL ORIGIN 
 As widely discussed in another review in this journal, 
adequate antiplatelet therapy is recommended for secondary 
prevention after cerebral ischaemia of presumed arterial ori-
gin. This evidence derived mainly from the results of three 
large trials [9-11], that investigated whether vitamin K an-
tagonists (VKAs) would be more effective than aspirin for 
this indication.  
 The SPIRIT trial [9] compared 30 mg daily aspirin 
against warfarin (INR target 3.0–4.5) in an open randomized 
trial of over a thousand stroke patients on sinus rhythm. Due 
to a high rate of hemorrhagic complications in the anticoagu-
lation group the study was terminated prematurely. Major 
systemic and intracranial hemorrhage rates were 8% in the 
warfarin group versus 1% in the aspirin group (hazard ratio 
[HR], 9.3; 95% CI, 4.0–22). The occurrence of ischemic 
events was similar in both groups (4.1% in both groups; HR, 
1.03; 95% CI, 0.6–1.75) including vascular death, nonfatal 
ischemic stroke, and nonfatal MI.  
 More conservative INR targets have also failed to estab-
lish an advantage of warfarin over aspirin as demonstrated 
by the WARSS trial [10], which tested INRs between 1.4 
and 2.8. 2.206 Patients with noncardioembolic stroke were 
included in this trial. The results show similarity in stroke 
recurrence and death in both groups, with an excess of sys-
temic bleeds in those allocated to warfarin. 
 The ESPRIT trial [11] randomized 1,068 patients with 
prior stroke or TIA to warfarin (INR target 2.0–3.0) or aspi-
rin, 30–325 mg, per day. Treatment was randomized but 
open; outcome event assessment was blinded. Event this 
study was prematurely terminated due to the fact that ran-
domization to the aspirin or aspirin plus dipyridamole inter-
vention was determined to be superior. There were no sig-
nificant differences in terms of primary outcome (stroke, MI, 
vascular death, or major bleeds) in the aspirin group com-
pared with warfarin, with an 18% event rate in the aspirin 
and 19% in the warfarin group (HR, 1.02; 95% CI, 0.77–
1.35). There was a nonsignificant trend toward a lower rate 
of ischemic stroke in the warfarin group (7.6% vs. 10.0%; 
HR, 0.76; 95% CI, 0.51–1.15), which was offset by a signifi-
cantly higher rate of major bleeding in this group (8.4% vs. 
3.4%; HR, 2.56; 95% CI, 1.48–4.43)  
 The absence of benefit, irrespective of the intensity of 
anticoagulation used, with a significant increase in risk of 
intracerebral haemorrhage on high-intensity anticoagulation 
(international normalised ratio [INR] 3) conditioned that 
the use of VKAs for this indication is not advised [12,13].  
 A rather different setting is the one of the WASID trial 
[14], in which high aspirin dose (1,3 g/day) was compared to 
dose-adjusted warfarin with an INR target between 2.0 and 
3.0 even in secondary prevention after a prior stroke in sub-
jects with atherosclerotic stenosis.  
 Five hundred sixty-nine patients with 50% stenosis 
were enrolled. There was no significant difference in recur-
rent stroke rate, with 22% recurrence over 1.8 years of fol-
low-up in the aspirin group and 22% in the warfarin group 
(HR, 1.04; 95% CI, 0.73–1.48). Enrollment was stopped 
early due to high rates of adverse events among the patients 
receiving warfarin, including death (4.3% in the aspirin 
group vs. 10% in the warfarin group; HR, 0.46; 95%CI, 
0.23–0.90; P=0.02), major hemorrhage (3% vs. 8%; HR, 
0.39; 95% CI, 0.18– 0.84; P=0.01), and MI and sudden death 
(3% vs. 7%; HR, 0.40; 95% CI, 0.18–0.91; P=0.02). So, de-
spite the fact that new anticoagulants actually under devel-
opment might provide greater benefits also for this indica-
tion, actually VKAs, also with more conservative INR tar-
gets, are not indicated in the secondary prevention of stroke 
with ascertained atherosclerotic origin.  
ANTICOAGULANTS IN PRIMARY AND SECON-
DARY PREVENTION OF CEREBROVASCULAR 
EVENTS IN PATIENTS WITH ATRIAL FIBRILLA-
TION  
 Randomized clinical trials have firmly established the 
value of antithrombotic therapies for reducing the risk of 
Antivitamin K Drugs in Stroke Prevention Current Vascular Pharmacology, 2013, Vol. 11, No. 00    3 
stroke in patients with previous cardioembolic stroke. 
Among the various cardiomyopathies, Atrial fibrillation (AF) 
is the most common source of cardiogenic brain embolism 
[15].  
 The prevalence of AF increases sharply with age: six 
percent of the population > 65 years of age has AF [16], and 
with increasing life expectancy, cardioembolic events are 
likely to become even more important.  
 Approximately 70% of patients with AF have non-
valvular atrial fibrillation (NVAF) associated with underly-
ing non-rheumatic heart disease, 20% have underlying 
rheumatic heart disease and 10% have lone atrial fibrillation 
without obvious structural heart disease [17]. 
 As reported in the introduction, about 20% of all TIAs 
and ischaemic strokes have a cardiac origin, most commonly 
atrial fibrillation. There is much variation, however, in the 
risk of stroke in patients with AF, which can be assessed 
with risk scoring systems such as the CHADS2-score [18]. 
However, a general assessment of risk estimates that patients 
with NVAF who present with TIA or stroke have a n overall 
risk of recurrent stroke of 12% in the first year and 5% per 
annum thereafter [19].  
 Efficacy of VKAs in prevention of embolism in subjects 
with nonvalvular AF is well established from many trials 
(AFASAK, BAATAF, SPINAF, CAFA) mainly comparing 
warfarin vs. placebo [20-23]. These trial found a relative risk 
reduction of 2.5% to 4.7% per year for ischemic stroke and 
absolute stroke rate reduction of 33% to 86%.  
 The AFASAK trial, tested the hypothesis of effectiveness 
of anticoagulation therapy with warfarin in prevention of 
thromboembolic complications in patients with chronic non-
rheumatic AF in comparison with placebo and aspirin 75 
mg/day [20]. This trial enrolled 1007 outpatients with 
chronic non-rheumatic AF: 335 received anticoagulation 
with warfarin openly, and in a double-blind study 336 re-
ceived aspirin 75 mg once daily and 336 placebo. Each pa-
tient was followed up for 2 years or until termination of the 
trial. The primary endpoint was a thromboembolic complica-
tion (stroke, transient cerebral ischaemic attack, or embolic 
complications to the viscera and extremities). The secondary 
endpoint was death. The incidence of thromboembolic com-
plications and vascular mortality were significantly lower in 
the warfarin group than in the aspirin and placebo groups, 
which did not differ significantly. 5 patients on warfarin had 
thromboembolic complications compared with 20 patients on 
aspirin and 21 on placebo. 21 patients on warfarin were 
withdrawn because of non-fatal bleeding complications 
compared with 2 on aspirin and none on placebo.  
 The BAATAF Trial [21], was an unblinded, randomized, 
controlled trial of long-term, low-dose warfarin therapy (tar-
get prothrombin-time ratio, 1.2 to 1.5) in patients with 
nonrheumatic AF, controlled with placebo or aspirin. A total 
of 420 patients entered the trial (212 in the warfarin group 
and 208 in the control group) and were followed for an aver-
age of 2.2 years. Prothrombin times in the warfarin group 
were in the target range 83 percent of the time. Only 10 per-
cent of the patients assigned to receive warfarin discontinued 
the drug permanently. There were 2 strokes in the warfarin 
group (incidence, 0.41 percent per year) as compared with 13 
strokes in the control group (incidence, 2.98 percent per 
year), for a reduction of 86 percent in the risk of stroke (war-
farin:control incidence ratio = 0.14; 95 percent confidence 
interval, 0.04 to 0.49; P = 0.0022). Long-term VKA use was 
effective in preventing stroke in patients with non-rheumatic 
AF. 
 The SPINAF trial [22], was a randomized, double-blind, 
placebo-controlled study to evaluate low-intensity anticoagu-
lation with warfarin (prothrombin-time ratio, 1.2 to 1.5) in 
571 men with chronic nonrheumatic AF (525 patients had 
not previously had a cerebral infarction, whereas 46 patients 
had previously had such an event)., controlled vs placebo. 
The primary end point was cerebral infarction; secondary 
end points were cerebral hemorrhage and death. Among the 
patients with no history of stroke, cerebral infarction oc-
curred in 19 of the 265 patients in the placebo group during 
an average follow-up of 1.7 years (4.3 percent per year) and 
in 4 of the 260 patients in the warfarin group during an aver-
age follow-up of 1.8 years (0.9 percent per year). The reduc-
tion in risk with warfarin therapy was 0.79 (95 percent con-
fidence interval, 0.52 to 0.90; P = 0.001). The annual event 
rate among the 228 patients over 70 years of age was 4.8 
percent in the placebo group and 0.9 percent in the warfarin 
group (risk reduction, 0.79; P = 0.02). The only cerebral 
hemorrhage occurred in a 73-year-old patient in the warfarin 
group. Other major hemorrhages, all gastrointestinal, oc-
curred in 10 patients: 4 in the placebo group, for a rate of 0.9 
percent per year, and 6 in the warfarin group, for a rate of 1.3 
percent per year. There were 37 deaths that were not pre-
ceded by a cerebral end point--22 in the placebo group and 
15 in the warfarin group (risk reduction, 0.31; P = 0.19). 
Cerebral infarction was more common among patients with a 
history of cerebral infarction (9.3 percent per year in the pla-
cebo group and 6.1 percent per year in the warfarin group) 
than among those without such a history. In this study also a 
lower INR target seems to guarantee protection against 
thromboembolic events in patients with AF. 
 The Canadian Atrial Fibrillation Anticoagulation Study 
[23] was a randomized double-blind placebo-controlled trial 
to assess the potential of warfarin to reduce systemic throm-
boembolism and its inherent risk of hemorrhage. As a result 
of the publication of two other "positive" studies of similar 
design and objective, this study was stopped early before 
completion of its planned recruitment of 630 patients. There 
were 187 patients randomized to warfarin and 191 to pla-
cebo. Permanent discontinuation of study medication oc-
curred in 26% of warfarin-treated and 23% of placebo-
treated patients. The target range of the international normal-
ized ratio was 2 to 3. The annual rates of the primary out-
come event cluster were 3.5% in warfarin-treated and 5.2% 
in placebo-treated patients, with a relative risk reduction of 
37% (95% confidence limits, -63.5%, 75.5%, p = 0.17), con-
firming effectiveness of VKA use vs placebo in this setting.  
 Current guidelines still regard VKAs at INR 2·0–3·0 to 
be the standard treatment after cerebral ischaemia of cardiac 
origin for patients who can tolerate them [24,25]. 
 Warfarin reduces the risk of recurrent stroke or systemic 
embolism by about 61% (95% CI 37–75%) compared with 
control in AF patients with recent TIA or ischaemic stroke. 
This proportional risk reduction is consistent with that ob-
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served for the prevention of first-ever stroke among indi-
viduals with AF, including the elderly [26,27]. 
 Warfarin also increases the odds of major extracranial 
haemorrhage (OR 4·3 [95% CI 1·5–12·1]) [27]. 
 The decision to prescribe warfarin, and the net clinical 
benefit of warfarin, is based on an accurate assessment of the 
likely absolute annual risk of stroke without warfarin, and 
whether the likely benefits of warfarin (a two-thirds reduc-
tion in absolute stroke risk) are likely to outweigh the risks 
of bleeding associated with warfarin use [28]. 
 More recently, several randomized trials have also been 
conducted comparing new anticoagulants compounds such 
as direct Factor Xa inhibitors (Apixaban, Rivaroxaban, 
Edoxaban, Betrixaban) [29] or direct Thrombin (F II) Inhibi-
tors (Ximelagatran, Dabigatran) [30-33] to high quality ad-
justed-dose warfarin in persons with atrial fibrillation. The 
relationship between new and old anticoagulant, the advan-
tages of oral administration, the better pharmacokinetic pro-
file, the rapid onset of the pharmacologic action, the lower 
interactions with food and drugs, and the predictivity of anti-
coagulant response without need of coagulation monitoring 
are matters of absolute interest and strict actuality, but these 
arguments exceed the aim of the present review.  
ANTIPLATELET VS ANTICOAGULANTS IN PRI-
MARY PREVENTION IN PATIENTS WITH ATRIAL 
FIBRILLATION AND IN SECONDARY PREVEN-
TION AFTER A CARDIOEMBOLIC STROKE 
 As showed before oral anticoagulants remain the treat-
ment of choice for secondary prevention of cardioembolic 
stroke. However, antiplatelet therapy provides an alternative 
when oral anticoagulation is contraindicated or when patient 
choice or compliance limits choice of therapy. Infact, despite 
the efficacy and affordability of warfarin, many patients with 
cardioembolic ischaemic stroke or TIA are not treated with 
warfarin because it is perceived to be inconvenient or haz-
ardous. For those who are treated, the long-term efficacy and 
safety of warfarin depends on maintaining a narrow range of 
anticoagulation intensity (INR 2·0–3·0). However, as previ-
ously underlined, this measure is often compromised by the 
patient’s dietary intake, exposure to other drugs, and coexist-
ing illnesses. Consequently, many drug-compliant patients 
are not well controlled. In recent, carefully monitored trials, 
patients treated with warfarin spent only 63–68% of the time 
in the therapeutic INR range [34-36]. However, in many 
clinical settings, time within this INR range is much lower 
[37], and many patients discontinue treatment [38]. Conse-
quently, alternative antithrombotic regimens of similar effi-
cacy to warfarin, but without the limitations, are needed, and 
antiplatelet drugs are perceived as an effective alternative. 
 Nevertheless of this, the superiority of warfarin over 
combination antiplatelet therapy for stroke prevention in 
nonvalvular atrial fibrillation has been shown in several tri-
als. A meta-analysis of 29 trials with 28,044 patients showed 
a 64% reduction in stroke in the warfarin group compared 
with 22% (95% CI, 0.49–0.74) in the antiplatelet groups 
(95% CI, 0.06–0.35) for a RR reduction of 39% (95% CI, 
0.22–0.52) [26,39].  
 Superiority of VKAs was demonstrated in comparison to 
different antiplatelet compounds either administrated in sin-
gle or in combination therapy. 
 Adjusted-dose warfarin reduces stroke by ~ 45% as com-
pared with aspirin [5].  
 The comparison between VKAs and aspirin in secondary 
prevention of stroke in patients with AF showed that ad-
justed-dose warfarin is significantly more effective than an-
tiplatelet therapy for preventing recurrent stroke (OR 0·49 
[95% CI 0·33–0·72]) [26].  
 Although major extracranial bleeding complications oc-
curred more often in patients on anticoagulants (OR 5·2 
[2·1–12·8]), the absolute difference was small (1·9%) [39].  
 The absolute benefit of oral anticoagulation (versus anti-
platelet therapy) increases as patients with AF get older be-
cause stroke risk increases with age and the relative efficacy 
of oral anticoagulation therapy to prevent ischaemic stroke 
does not change. However, the relative efficacy of antiplate-
let therapy to prevent ischaemic stroke seems to decrease as 
patients with AF get older. 
 The SPAF I trial [40], was a multicenter, randomized 
trial, compared 325 mg/day aspirin (double-blind) or war-
farin with placebo for prevention of ischemic stroke and sys-
temic embolism (primary events), and included 1,330 inpa-
tients and outpatients with constant or intermittent AF. Dur-
ing a mean follow-up of 1.3 years, the rate of primary events 
in patients assigned to placebo was 6.3% per year and was 
reduced by 42% in those assigned to aspirin (3.6% per year; 
p = 0.02; 95% confidence interval, 9-63%). In the subgroup 
of warfarin-eligible patients (most less than 76 years old), 
warfarin dose-adjusted to prolong prothrombin time to 1.3-
fold to 1.8-fold that of control reduced the risk of primary 
events by 67% (warfarin versus placebo, 2.3% versus 7.4% 
per year; p = 0.01; 95% confidence interval, 27-85%). Pri-
mary events or death were reduced 58% (p = 0.01) by war-
farin and 32% (p = 0.02) by aspirin. The risk of significant 
bleeding was 1.5%, 1.4%, and 1.6% per year in patients as-
signed to warfarin, aspirin, and placebo, respectively. 
 Aspirin and warfarin are both effective in reducing 
ischemic stroke and systemic embolism in patients with 
atrial fibrillation. Because warfarin-eligible patients com-
posed a subset of all aspirin-eligible patients, the magnitude 
of reduction in events by warfarin versus aspirin cannot be 
compared. Because of too few events occurred in warfarin-
eligible patients to directly assess the relative benefit of aspi-
rin compared with warfarin, the trial was continued to ad-
dress this issue. 
 Due to the lack of direct comparison of warfarin with 
aspirin In the first SPAF-I study, caused by the small number 
of thromboembolic events in the follow-up, SPAF-II [41] 
aimed to address this issue and also to assess the differential 
effects of the two treatments according to age. We compared 
warfarin (prothrombin time ratio 1.3-1.8, international nor-
malised ratio 2.0-4.5) with aspirin 325 mg daily for preven-
tion of ischaemic stroke and systemic embolism (primary 
events) in two parallel randomised trials involving 715 pa-
tients aged 75 years or less and 385 patients older than 75; 
we sought reductions in the absolute rate of primary events 
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by warfarin compared with aspirin of 2% per year and 4% 
per year, respectively. In the younger patients, warfarin de-
creased the absolute rate of primary events by 0.7% per year 
(95% CI-0.4 to 1.7). The primary event rate per year was 
1.3% with warfarin and 1.9% with aspirin (relative risk [RR] 
0.67, p = 0.24). The absolute rate of primary events in low-
risk younger patients (without hypertension, recent heart 
failure, or previous thromboembolism) on aspirin was 0.5% 
per year (95% CI 0.1 to 1.9). Among older patients, warfarin 
decreased the absolute rate of primary events by 1.2% per 
year (95% CI-1.7 to 4.1). The primary event rate per year 
was 3.6% with warfarin and 4.8% with aspirin (RR 0.73, p = 
0.39). In this older group, the rate of all stroke with residual 
deficit (ischaemic or haemorrhagic) was 4.3% per year with 
aspirin and 4.6% per year with warfarin (RR 1.1). Warfarin 
may be more effective than aspirin for prevention of ischae-
mic stroke in patients with atrial fibrillation, but the absolute 
reduction in stroke rate by warfarin is small. Younger pa-
tients without risk factors had a low rate of stroke when 
treated with aspirin. In older patients the rate of stroke 
(ischaemic and haemorrhagic) was substantial, irrespective 
of which agent was given. Patient age and the inherent risk 
of thromboembolism should be considered in the choice of 
antithrombotic prophylaxis for patients with atrial fibrilla-
tion. 
 The European Atrial Fibrillation Trial (EAFT) [19] com-
pared the outcome of treatment with oral anticoagulants, 
aspirin or placebo in patients with persistent or paroxysmal 
NVAF who had experienced a cardioembolic TIA or minor 
ischaemic stroke in the preceding 3 months. Patients with no 
contraindications to VKAs were randomly allocated to VKA 
(INR 2·5–4·0), aspirin (300 mg daily), or placebo, and pa-
tients with contraindications to VKAs were allocated to aspi-
rin versus placebo only. VKA was the most effective treat-
ment (HR for VKA vs placebo for vascular death, myocar-
dial infarction, stroke, or systemic emboli, 0·53, 0·36–0·79, 
with an absolute risk reduction of about 8% annually. The 
HR for VKA versus aspirin was 0·60 (0·41–0·87), although 
aspirin was of some value in patients ineligible for VKAs 
(0·83, 0·65–1·05). VKAs were more effective than aspirin at 
preventing recurrent stroke (p,0.001). Although there was a 
trend towards benefit, the reduction in the annual risk of re-
current stroke with aspirin (10%, n=404) compared with 
placebo (12%, n=378) did not reach significance 
(p=0.31).There were more major haemorrhages with VKA, 
but the benefits clearly outweighed this risk [42]. 
 The findings of EAFT were corroborated in those pa-
tients with previous TIA or ischaemic stroke who were en-
rolled in SPAF III [43], was designed to evaluate effective-
ness of alternative therapy than high dose VKAs (with INR 
between 2 and 3), in high risk patients with AF. 1044 pa-
tients with AF and with at least one thromboembolic risk 
factor (congestive heart failure or left ventricular fractional 
shortening < or = 25%, previous thromboembolism, systolic 
blood pressure of more than 160 mm Hg at study enrollment, 
or being a woman aged over 75 years) were randomly as-
signed either a combination of low-intensity, fixed-dose war-
farin (international normalised ratio [INR] 1.2-1.5 for initial 
dose adjustment) and aspirin (325 mg/day) or adjusted-dose 
warfarin (INR 2.0-3.0). Drugs were given open-labelled. The 
mean INR during follow-up of patients taking combination 
therapy (n = 521) was 1.3, compared with 2.4 for those tak-
ing adjusted-dose warfarin (n = 523). During follow-up, 54% 
of INRs in patients taking combination therapy were 1.2-1.5 
and 34% were less than 1.2. SPAF III trial was halted early, 
after a mean, follow-up of 1.1 years, because patients allo-
cated to fixed low-dose VKA (INR 1·2–1·5) plus aspirin 325 
mg daily had four times more ischaemic strokes during fol-
low-up than did those allocated to regular VKA (INR 2·0–
3·0) at an interim analysis (p < 0.0001). The annual rates of 
disabling stroke (5.6% vs 1.7%, p = 0.0007) and of primary 
event or vascular death (11.8% vs 6.4%, p = 0.002), were 
also higher with combination therapy. The rates of major 
bleeding were similar in both treatment groups. So, Low-
intensity, fixed-dose warfarin plus aspirin in this regimen is 
insufficient for stroke prevention in patients with non-
valvular AF at high-risk for thromboembolism. 
 The only other trial apart from EAFT run solely in pa-
tients with recent cerebral ischaemia and atrial fibrillation, 
comparing VKAs and indobufen, found 15% fewer primary 
outcomes with VKA than with ithe antiplatelet drug [44]. 
 The ACTIVE-W trial compared warfarin (with an INR 
target between 2 and 3) to combination clopidogrel (75 mg 
once daily) plus aspirin (75–100 mg daily) ramdomly as-
signed in 6,706 patients with AF. After a median follow-up 
of 1·3 years, the annual occurrence of stroke, systemic em-
bolization, myocardial infarction, or vascular death was 
3.9% in the warfarin group and 5.6% in the double antiplate-
let group (RR, 1.44; 95% CI, 1.18–1.76; P=0.0003). There 
was no significant difference in major bleeding between the 
two treatment groups (2·4% per year for those on clopidogrel 
plus aspirin vs 2·2% per year on warfarin; RR 1·10 [0·83–
1·45]) Due to a clear benefit in the warfarin group, the study 
was stopped prematurely, confirming how VKAs are more 
effective also than the association aspirin + clopidogrel [45].  
 A subgroup analysis of this trial addressed the hypothesis 
that most of the benefit of warfarin over the combination of 
aspirin and clopidogrel was in patients who were already 
taking and tolerating oral anticoagulant therapy. Results of 
this analysis suggest that patients who were already taking 
warfarin at study entry and were randomly assigned to con-
tinue oral anticoagulation therapy had a substantial reduction 
in vascular events compared with those on the combination 
of clopidogrel and aspirin. Conversely, patients who were 
not taking oral anticoagulants at study entry and were ran-
domly assigned to start oral anticoagulation had a similar 
rate of vascular events (4·7% vs 5·9% per year; RR 0·79 
[0·53–1·18]) compared with those on the combination of 
clopidogrel and aspirin [45].  
 In this chapter, nevertheless is not tested the efficacy of 
VKAs, should be cited the ACTIVE-A trial, that enrolled 
patients with cardioembolic stroke deemed unsuitable for 
warfarin therapy, either due to risk of bleeding, physician 
judgment, or patient preference. The effects of combination 
aspirin and clopidogrel versus aspirin and placebo on secon-
dary stroke prevention were compared in 7,554 patients over 
a mean follow-up period of 3.6 years. Only 13% of partici-
pants had history of stroke or TIA. The clopidogrel group 
experienced major vascular events at a rate of 6.8% per year, 
compared with 7.6% per year in the control group (RR, 0.89; 
95% CI, 0.81–0.98). The risk reduction was largely due to a 
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significant reduction of ischemic strokes, with rates of 1.9% 
versus 2.8% per year in the clopidogrel and control groups, 
respectively (RR, 0.68; 95% CI, 0.57–0.80). 
 However, this therapeutic benefit was hampered by a 
high incidence of systemic and intracranial hemorrhage. An-
nual rates of any major bleeding in the clopidogrel and con-
trol groups, respectively, were 2.0% versus 1.3% (RR, 1.57; 
95% CI, 1.29–1.92) and rates of intracranial bleeding were 
0.4% versus 0.2% (RR, 1.87; 95% CI, 1.19–2.94) [46]. 
These data suggest that treating 1000 patients with AF for 1 
year with clopidogrel plus aspirin prevents eight major vas-
cular events (including two fatal and three disabling strokes) 
and causes seven major haemorrhages (one fatal) compared 
with aspirin alone. 
 Because of the frequent finding of co-existence in the 
same patients of the need of both anticoagulant and antiplate-
let therapy (AF + ischemic heart disease, AF + peripheral 
artery disease, etc), both warfarin and aspirin are thought to 
be needed to prevent thrombus formation in the left atrium 
and arteries.  
 VKAs prevent the formation of fibrin-rich thrombus (so-
called “red clot”) associated with AF, whereas antiplatelet 
treatment prevents the formation of the platelet-rich throm-
bus (so-called “white clot”) associated with arterial vascular 
disease. This principle applies particularly to patients with 
AF who present with unstable vascular disease manifest by 
an acute coronary syndrome, or who are undergoing vascular 
injury by means of percutaneous coronary or carotid inter 
vention or stenting, for which aspirin plus clopidogrel is rec-
ommended. For such patients with AF, the long-term bene-
fit-to-harm ratio of combination therapy is not known and 
should be left to the clinician’s discretion. 
 However, for patients with AF who have stable vascular 
disease, there is no reliable evidence to indicate that adding 
aspirin (or clopidogrel) to warfarin is safe and effective 
compared with warfarin alone. Indeed, warfarin can be an 
effective drug for stable coronary and cerebrovascular dis-
ease, and the haemorrhage rate seems to be greater with the 
combination of aspirin and warfarin [47-49].  
CONCLUSIONS 
 Data available provide the indication to long term use of 
VKAs as treatment of choice for secondary stroke prevention 
in patients who have had a recent TIA or ischaemic stroke of 
cardioembolic origin. If warfarin is prescribed, one should 
aim for a target INR between the range 2–3 to achieve the 
best balance between adequate secondary prevention of car-
dioembolic events and the risk of major haemorrhagic com-
plications. 
 If warfarin is contraindicated, long-term antiplatelet 
treatment with aspirin is a safe, but much less effective than 
VKAs; alternative treatment option that should be considered 
pending future data on the efficacy of, and potential licens-
ing of, direct thrombin inhibitors and other new anticoagu-
lant compounds actually under development. 
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